Lundh B L, Nilsson S E
Department of Ophthalmology, Linköping University, Sweden.
Acta Ophthalmol (Copenh). 1990 Dec;68(6):658-60. doi: 10.1111/j.1755-3768.1990.tb01689.x.
Simvastatin, a potent blood lipid reducer, has been suspected of inducing cataract in dogs. Twenty-nine type II hyperlipidemic patients on simvastatin were followed over 2 years at half-year intervals. A parallel group of sex- and age-matched normolipidemics were followed over a half year. Patients and controls had similar nuclear and cortical lens opacities, and water clefts. Vacuole number did not differ significantly between right and left eyes, nor between nasal and temporal parts of the lenses. General vacuole index (total vacuole number in a patient) for left eyes was analysed further. Controls showed significantly higher indices than patients, for no obvious reason. Indices for controls increased significantly over the half-year test period, and among patients over each half-year interval. The speed of this increase did not differ significantly from that of the controls. Furthermore, the increase was judged to be clinically insignificant. No deleterious effect of simvastatin on the lens could be established.
辛伐他汀是一种强效的血脂降低药物，曾被怀疑会诱发犬类白内障。29名服用辛伐他汀的II型高脂血症患者被随访2年，每隔半年进行一次检查。一组年龄和性别匹配的血脂正常者作为平行对照组，随访半年。患者和对照组的晶状体核性和皮质性混浊以及水裂情况相似。左右眼之间以及晶状体鼻侧和颞侧的空泡数量没有显著差异。对左眼的总体空泡指数（患者的总空泡数）进行了进一步分析。对照组的指数明显高于患者组，但原因不明。在半年的测试期内，对照组的指数显著增加，患者组在每个半年间隔内也有增加。这种增加的速度与对照组没有显著差异。此外，这种增加被认为在临床上无显著意义。无法确定辛伐他汀对晶状体有有害影响。
